Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze

被引:19
|
作者
Olivares, Orianne [1 ,2 ,3 ,4 ]
Vasseur, Sophie [1 ,2 ,3 ,4 ]
机构
[1] INSERM U1068, CRCM, F-13009 Marseille, France
[2] Inst Paoli Calmettes, F-13009 Marseille, France
[3] CNRS, CRCM, UMR7258, F-13009 Marseille, France
[4] Univ Aix Marseille, F-13284 Marseille, France
关键词
pancreatic cancer; metabolism; non-essential amino acids; proline; MAGNETIC-RESONANCE-SPECTROSCOPY; ARGININE DEPRIVATION; ENERGY-EXPENDITURE; PYRUVATE-KINASE; ONCOGENIC KRAS; MOUSE MODEL; K-RAS; CANCER; BIOLOGY; PROLINE;
D O I
10.1002/ijc.29501
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a debilitating and almost universally fatal malignancy. Despite advances in understanding of the oncogenetics of the disease, very few clinical benefits have been shown. One of the main characteristics of PDAC is the tumor architecture where tumor cells are surrounded by a firm desmoplasia. By reducing vascularization, thus both oxygen and nutrients delivery to the tumor, this stroma causes the appearance of hypoxic zones driving metabolic adaptation in surviving tumor cells in order to cope with challenging conditions. This metabolic reprogramming promoted by environmental constraints enhances PDAC aggressiveness. In this review, we provide a brief overview of previous works regarding the importance of glucose and glutamine addiction of PDAC cells. In particular we aim to highlight the need for exploring the impact of metabolites other than glucose and glutamine, such as non-essential amino acids and oncometabolites, to find new treatments. We also discuss the need for progress in methodology for metabolites detection. The overall purpose of our review is to emphasize the need to look beyond what is currently known, with a focus on amino acid availability, in order to improve our understanding of PDAC biology.
引用
收藏
页码:787 / 796
页数:10
相关论文
共 50 条
  • [21] Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
    Pervin, Jannat
    Asad, Mohammad
    Cao, Shaolong
    Jang, Gun Ho
    Feizi, Nikta
    Haibe-Kains, Benjamin
    Karasinska, Joanna M.
    O'Kane, Grainne M.
    Gallinger, Steven
    Schaeffer, David F.
    Renouf, Daniel J.
    Zogopoulos, George
    Bathe, Oliver F.
    FRONTIERS IN GENETICS, 2023, 14
  • [22] Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications
    Gong, Ruining
    Hu, Yonglu
    Yu, Qian
    Fang, Lin
    Ren, He
    JOURNAL OF PANCREATOLOGY, 2023, 6 (04) : 185 - 195
  • [23] Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
    Gautam, Shailendra K.
    Batra, Surinder K.
    Jain, Maneesh
    MOLECULAR CANCER, 2023, 22 (01)
  • [24] The intratumoral metabolic characterization and potential mechanisms in pancreatic ductal adenocarcinoma
    Luo, D.
    Li, Y.
    Ji, L.
    Gong, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S1497 - S1497
  • [25] Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
    Rai, Vikrant
    Agrawal, Swati
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 24
  • [26] Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A
    Del Aguila, Eduardo Mere
    Tang, Xiao-Han
    Gudas, Lorraine J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 291 - 298
  • [27] New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
    Ritu Raj Singh
    Eileen M. O’Reilly
    Drugs, 2020, 80 : 647 - 669
  • [28] New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma
    Mangge, Harald
    Niedrist, Tobias
    Renner, Wilfried
    Lyer, Stefan
    Alexiou, Christoph
    Haybaeck, Johannes
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (28) : 3012 - 3024
  • [29] hnRNPLL: A new pancreatic ductal adenocarcinoma therapeutic target
    Ping, Changyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 111 - 111
  • [30] hnRNPLL: A new pancreatic ductal adenocarcinoma therapeutic target
    Ping, Changyun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 111 - 111